These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18415955)

  • 1. FDA notifications. FDA revises Baraclude labeling for HIV patients.
    AIDS Alert; 2007 Sep; 22(9):103-4. PubMed ID: 18415955
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA, Bristol-Myers Squibb issue warning on hepatitis B drug.
    AIDS Read; 2007 Oct; 17(10):478-510. PubMed ID: 17987701
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA notifications. Entecavir (Baraclude®) labeling changed.
    AIDS Alert; 2010 Dec; 25(12):141-2. PubMed ID: 21328814
    [No Abstract]   [Full Text] [Related]  

  • 4. Common hepatitis B drug linked to HIV antiviral resistance.
    Future Microbiol; 2007 Apr; 2(2):104. PubMed ID: 17687802
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA notifications. Entecavir revision made by FDA and BMS.
    AIDS Alert; 2007 Apr; 22(4):43. PubMed ID: 17595722
    [No Abstract]   [Full Text] [Related]  

  • 6. Entecavir in HIV/HBV coinfection: possible HIV activity and resistance risk.
    AIDS Clin Care; 2007 Apr; 19(4):32. PubMed ID: 17695090
    [No Abstract]   [Full Text] [Related]  

  • 7. Very few hepatitis trials recruiting.
    AIDS Patient Care STDS; 1998 Apr; 12(4):319-20. PubMed ID: 11361965
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. FDA draft guidance on Hepatitis C/HIV coinfection.
    AIDS Alert; 2010 Nov; 25(11):129-30. PubMed ID: 21128355
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA notifications. Entecavir is approved for chronic hepatitis B infection in adults.
    AIDS Alert; 2005 Jul; 20(7):83-4. PubMed ID: 16114113
    [No Abstract]   [Full Text] [Related]  

  • 10. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

  • 11. Entecavir.
    Opio CK; Lee WM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Jul; 4(7):535-6. PubMed ID: 16075486
    [No Abstract]   [Full Text] [Related]  

  • 12. Changing landscape of antiviral resistance management in chronic hepatitis B.
    Nguyen T; Locarnini S; Desmond P
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1314-7. PubMed ID: 18853991
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA notifications. Updates made to Reyataz package insert.
    AIDS Alert; 2008 Oct; 23(10):116-7. PubMed ID: 18935687
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA notifications. Kaletra revisions to packaging approved.
    AIDS Alert; 2010 Mar; 25(3):34. PubMed ID: 20629261
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA notifications. Lopinavir/ritonavir label updated.
    AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18727173
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA notifications. FDA grants approval for raltegravir.
    AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-hepatitis B virus coinfection: questions and answers.
    Valenti WM
    AIDS Read; 2005 May; 15(5):226-30. PubMed ID: 15900632
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment: triple infection with HIV and hepatitis B and C viruses--lesson in combination therapy.
    Dore GJ
    AIDS Read; 2004 Jul; 14(7):392. PubMed ID: 15282869
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis B virus infection.
    Dienstag JL
    N Engl J Med; 2008 Oct; 359(14):1486-500. PubMed ID: 18832247
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses.
    Soriano V; Sheldon J; García-Gasco P; Vispo E
    AIDS; 2007 Oct; 21(16):2253-4. PubMed ID: 18090058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.